Specifically, the designed peptides were furnished to serve as antidotes to SARS-CoV-2 spike protein-mediated infection of human ACE2-expressing cells. Delightfully, the peptides were found to be endowed with substantial binding affinity for ACE2 and a neutralizing antibody against the SARS-CoV-2 RBD. The gene discussed is ACE2; the disease is infection.